Pure Global AI
NCT06110793Not yet recruiting

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

A Phase Ib/II Trial of Lenvatinib Plus Pembrolizumab Plus Fulvestrant in ER-positive/ HER2- Negative Metastatic Breast Cancer
Memorial Sloan Kettering Cancer CenterPhase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Metastatic Breast Cancer
Drug/Device/Intervention
Lenvatinib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Memorial Sloan Kettering Cancer Center
Location
Basking Ridge,Middletown,Montvale,Commack,Harrison,New York,Uniondale, United States of America
Timeline & enrollment
Phase
Phase 1/2
Start date
Nov 01, 2023
End date
Nov 01, 2026
Enrollment
43 participants
Primary outcome

The number of adverse events and dose-limiting toxicities to find the Recommended Phase 2 Dose (RP2D)

Summary

The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab,
 and fulvestrant is a safe and effective treatment that causes few or mild side effects in
 people with ER+/HER2- metastatic breast cancer.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastMalignant neoplasm: Breast, unspecifiedMalignant neoplasm: Central portion of breastMalignant neoplasm: Overlapping lesion of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06110793
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06110793 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Not yet recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 43 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.